SCHEMBL2856724

SCHEMBL2856724

N[C@@H](CCCCN1CCC(c2nc3ccc(Cl)cc3s2)CC1)C(=O)N1CCSC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DPP7 Q9UHL4 5/20 0.43
DPP4 P27487 5/20 0.43
DPP8 Q6V1X1 2/20 0.43
DPP9 Q86TI2 2/20 0.43
MAPT P10636 5/20 0.41
HTT P42858 2/20 0.41
LMNA P02545 1/20 0.41
FPR3 P25089 1/20 0.40
FPR2 P25090 1/20 0.40
TP53 P04637 2/20 0.40
POLB P06746 1/20 0.40
GAA P10253 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
ALDH1A1 P00352 1/20 0.38
KMT2A Q03164 1/20 0.38
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
UBE2M P61081 2/20 0.37
DCUN1D1 Q96GG9 2/20 0.37
P2RX3 P56373 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2856727 1.00 DPP7 (0.43) DPP7DPP4DPP8DPP9MAPT
SCHEMBL2854152 0.93 DPP7 (0.43) DPP7DPP4DPP8DPP9MAPT
SCHEMBL2854147 0.93 DPP7 (0.43) DPP7DPP4DPP8DPP9MAPT
SCHEMBL2854236 0.88 SMN1; SMN2 (0.51) DPP7DPP4DPP8DPP9MAPT
SCHEMBL2854239 0.88 SMN1; SMN2 (0.51) DPP7DPP4DPP8DPP9MAPT
SCHEMBL2857698 0.88 DPP4 (0.45) DPP7DPP4DPP8DPP9GAA
SCHEMBL2857690 0.88 DPP4 (0.45) DPP7DPP4DPP8DPP9GAA
SCHEMBL2857447 0.88 DRD2 (0.44) DPP7DPP4DPP8DPP9MAPT
SCHEMBL2857451 0.88 DRD2 (0.44) DPP7DPP4DPP8DPP9MAPT
SCHEMBL2855953 0.85 NPC1 (0.53) DPP7DPP4DPP8DPP9MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7790725-B2 Thiazolidine derivatives and medicinal use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-09-07 US disclosed
US-20070259880-A1 THIAZOLIDINE DERIVATIVES AND MEDICINAL USE THEREOF MITSUBISHI PHARMA CORPORATION (JP) 2007-11-08 US disclosed
US-20040259883-A1 Thiazolidine derivative and medicinal use thereof MITSUBISHI PHARMA CORPORATION (JP) 2004-12-23 US disclosed
EP-1426366-A1 THIAZOLIDINE DERIVATIVE AND MEDICINAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2004-06-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070259880-A1 THIAZOLIDINE DERIVATIVES AND MEDICINAL USE THEREOF DPP4, DPP7, DPP3 DPP7 2/4885DPP4 1/4885DPP8 5/4885
US-20040259883-A1 Thiazolidine derivative and medicinal use thereof DPP4, DPP7, DPP3 DPP7 2/4885DPP4 1/4885DPP8 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.